abstract |
The present invention relates to a therapeutic agent for ophthalmic diseases, which comprises a vascular endothelial growth factor (VEGF) receptor inhibitor or an epithelial growth factor (EGF) receptor inhibitor, which is in the form of nanoparticles and has a property of staying in the posterior segment tissue when administered systemically will be. |